Please login to the form below

Not currently logged in
Email:
Password:

classical Hodgkin's lymphoma

This page shows the latest classical Hodgkin's lymphoma news and features for those working in and with pharma, biotech and healthcare.

BMS gets OK for monthly Opdivo dosing

BMS gets OK for monthly Opdivo dosing

The majority of patients treated with Bristol-Myers Squibb’s checkpoint inhibitor Opdivo will receive fewer injections after the FDA cleared a four-weekly dosing regimen for the drug. ... and classical Hodgkin’s lymphoma, said BMS in a statement.

Latest news

  • Merck takes on Roche with first-line bladder OK for Keytruda Merck takes on Roche with first-line bladder OK for Keytruda

    avelumab), AstraZeneca's Imfinzi (durvalumab) - have approval as second-line therapies for the cancer. ... for non-small cell lung cancer (NSCLC) and classical Hodgkin's lymphoma.

  • Keytruda and Opdivo backed for new uses in Europe Keytruda and Opdivo backed for new uses in Europe

    MSD and Bristol-Myers Squibb (BMS) both picked up positive opinions for their PD-1 inhibitors from the EMA's advisory committee last week. ... The Committee for Medicinal Products for Human Use (CHMP) gave a green light to MSD's Keytruda (pembrolizumab)

  • Keytruda closes in on Opdivo's lead in Hodgkin lymphoma Keytruda closes in on Opdivo's lead in Hodgkin lymphoma

    Keytruda closes in on Opdivo's lead in Hodgkin lymphoma. KEYNOTE-087 trial shows an overall response rate of 69 percent. ... For a few months Bristol-Myers Squibb's Opdivo has been the only checkpoint inhibitor approved for Hodgkin lymphoma, but rival

  • Merck closes in on first-line NSCLC label for Keytruda in US Merck closes in on first-line NSCLC label for Keytruda in US

    with Keytruda compared to chemotherapy is welcome news," commented Merck's head of R&D Roger Perlmutter. ... Along with second-line NSCLC, Opdivo is also approved for treating melanoma, renal cell carcinoma and classical Hodgkin's lymphoma, with an

  • Keytruda cleared in Europe for lung cancer Keytruda cleared in Europe for lung cancer

    Opdivo has a key advantage in NSCLC in that it is approved for all patients - regardless of PD-L1 status - as well as for renal cell carcinoma and classical Hodgkin's ... lymphoma. This is reflected in financial terms, with BMS reporting $1.54bn in sales

More from news
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics